<DOC>
	<DOC>NCT01896739</DOC>
	<brief_summary>To evaluate and compare the immunogenicity of Eutravac (Diphtheria-Tetanus-acellular Pertussis [DTaP] Hepatitis B [HB] combined) vaccine with separate but simultaneous administrations of DTaP and HB vaccine each administered to healthy infants, as measured by seroprotection/vaccine response rates 4-8 weeks post-final immunisation.</brief_summary>
	<brief_title>A Phase III Study to Assess the Immunogenicity and Safety of Eutravac (DTap-HB Combined Vaccine) With DTaP and Hepatitis B Vaccines in Healthy Infants</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Were healthy, male or female infants born at full term pregnancy (≥37 weeks) with a birth weight ≥2.5 kg to mothers with a negative HBsAg serology, documented prior to giving birth as per routine, sitespecific antenatal care procedures. Signed parental or legally acceptable representative's informed consent was obtained Evidence of an acute febrile illness with axillary temperature ≥37.5℃ on the day of the vaccination. Infants with symptoms of minor illness eg, mild gastroenteritis, mild upper respiratory tract infection and who did not have a temperature ≥37.5℃ on the day of the vaccination could be included at the Investigator's discretion History of diphtheria, tetanus, pertussis or hepatitis B disease History of any vaccinerelated hypersensitivity or anaphylactic reaction after previous administration of Euvax B</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Healthy infants with over than 37 weeks gestation periods.</keyword>
	<keyword>over than 2.5Kg at at birth weight.</keyword>
</DOC>